Publications by authors named "Guy Hannah"
Background: Resistance or intolerance to the available tyrosine kinase inhibitors (TKIs) remains a treatment challenge for patients with chronic myeloid leukaemia. We aimed to report the safety, antileukaemic activity, and pharmacokinetics of oral vodobatinib, a novel selective BCR::ABL1 TKI, in patients with Philadelphia chromosome-positive (Ph-positive) chronic myeloid leukaemia who previously received at least three TKIs, including ponatinib and asciminib.
Methods: This open-label, multicentre, phase 1/2 trial was conducted at 28 clinical sites across ten countries (Belgium, France, Hungary, India, Italy, Romania, South Korea, Spain, UK, and the USA).
Article Synopsis
- - Asciminib is a targeted treatment for BCR::ABL1 that minimizes side effects from disrupting other kinases, with a study of 49 patients showing it is generally well tolerated over a median follow-up of 14 months.
- - Most patients (59%) continued treatment, with only 12% stopping due to intolerance; however, treatment cessation was primarily due to intolerance rather than drug resistance (65% vs. 35%).
- - Out of 44 patients evaluated, 66% achieved a complete cytogenetic response, with lower success rates seen in patients with specific genetic variants; further analysis indicated that the drug can influence the growth of certain resistant cancer cell populations.
Article Synopsis
- The study examines the likelihood of treatment-free remission (TFR) among Chronic Myeloid Leukemia (CML) patients with different chromosomal characteristics.
- It categorizes patients into groups based on additional chromosomal abnormalities (ACA/Var-Ph group), those with only the classical Philadelphia translocation (c-Ph group), and high-risk ACA (HR-ACA subgroup) or variant Philadelphia translocations (Var-Ph subgroup).
- Findings aim to uncover how these chromosomal variations impact the probability of achieving TFR in CML patients, which is important for treatment decisions.
Haploidentical Transplant with Post-Transplant Cyclophosphamide for Acute Myeloid Leukaemia and Myelodysplastic Syndromes Patients: The Role of Previous Lines of Therapy.
Mediterr J Hematol Infect Dis
January 2024
Background: Allogeneic haematopoietic stem-cell transplant is an option, potentially curative, for high-risk acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) patients. Post-transplant cyclophosphamide administration allows for the selection of haploidentical donors in patients who are eligible for the procedure but do not have a fully matched donor since it can overcome the HLA barrier. There is still an active debate on whether intensifying the conditioning regimen is necessary with haploidentical donors when peripheral blood stem cells are used as the graft source.
View Article and Find Full Text PDFArticle Synopsis
- Allogeneic hematopoietic stem cell transplantation (HSCT) is an effective treatment for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), focusing on reducing transplantation-related mortality (TRM) with strategies like the HCT-CI score and age limits for conditioning.
- A study evaluated patients conditioned with fludarabine and myeloablative busulfan (FB4), showing a 2-year overall survival (OS) rate of 72% for those under 55 and 51% for those 55 and older, with better outcomes for older patients with lower comorbidity scores.
- The research highlights that age shouldn't be the only factor in determining conditioning intensity
During the COVID-19 pandemic, access to health services has been considerably restricted and furthermore, patients have been reluctant to attend for routine monitoring, and this may have had a negative impact in the management of patients affected with haematological disorders. Sudden blast crisis in chronic myeloid leukaemia is categorized as a rapid onset of blastic phase, after a documented 'optimal' response to tyrosine kinase inhibitor (TKI) therapy and within 3 months of a normal complete blood count. Herein, we describe a case of patient who developed sudden blast crisis after TKI while in treatment-free remission.
View Article and Find Full Text PDFBackground: The U- phenotype is extremely rare and is found predominantly in black African populations at a frequency of between 0.2 and 1.7%.
View Article and Find Full Text PDF